

ASX Announcement

Medibio Limited – 27 June 2018



Peer-reviewed Neurology Publication on Medibio Science

Sydney, Australia and Minneapolis, MN USA – 27 June 2018: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, announces that a clinical article by Defillo et al. titled “Physiological Differences between Mood Disorder Phenotypes Based on Heart Rate Variability” has been accepted for publication in EC Neurology, an internationally peer-reviewed journal.

Research was based on the 24-hour heart rate patterns of 301 consecutive patients with diagnosis of either normal, anxiety, depression or mixed. The publication highlights Medibio’s scientific success with predicting diagnoses using multinomial logistic regression analysis. The article concludes that distinct heart rate patterns clearly differentiate mood disorder diagnostic groups from normal controls. The reproducible and consistent findings reveal a new opportunity to improve the accuracy of psychiatric diagnosis using distinct patterns of mean heart rate and heart rate variability.

EC Neurology focuses on worldwide research in neuroscience with the mission to publish relevant and major advancements in neurological medicine, disorders, and treatments. The Managing Editor at EC Neurology noted, “**Publishing quality articles from eminent researchers like you is a huge asset for the journal. Your article is of eminent value that provides novel information to the research community.**”

- ENDS -

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Further Information:

Website: www.medibio.com.au

Shareholder and Investor Inquiries:

Stephanie Ottens
Investor Relations Director
Medibio Limited
stephanie.ottens@medibio.com.au
T: +61 434 405 400

Media Inquiries:

Josh Purdy
Senior Public Relations Manager
Medibio Limited
josh.purdy@medibio.com.au
T: +1 952-222-0551 ext. 208
M: +1 612-695-0168